Septerna, Inc. (NASDAQ:SEPN - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $28.99 and last traded at $27.09, with a volume of 365987 shares. The stock had previously closed at $24.28.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on SEPN shares. TD Cowen initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They issued a "buy" rating for the company. JPMorgan Chase & Co. began coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an "overweight" rating and a $38.00 price objective for the company. Cantor Fitzgerald assumed coverage on Septerna in a research report on Tuesday, November 19th. They set an "overweight" rating and a $50.00 target price on the stock. Finally, Wells Fargo & Company began coverage on Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $43.00 price target on the stock.
Read Our Latest Stock Report on SEPN
Septerna Trading Down 4.4 %
The firm's fifty day moving average price is $23.61.
Insider Buying and Selling at Septerna
In other Septerna news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the firm's stock in a transaction on Monday, October 28th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the completion of the purchase, the insider now owns 6,215,591 shares in the company, valued at $111,880,638. This represents a 6.34 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
See Also
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
